Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T34867
|
||||
Target Name |
Poly ADP ribose polymerase (PARP)
|
||||
Target Type |
Successful
|
||||
Disease | Acute ischemic stroke [ICD9: 434.91; ICD10: I61-I63] | ||||
Breast cancer; Ovarian cancer [ICD9: 174, 175, 183; ICD10: C50, C56] | |||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Brain cancer [ICD9: 191, 225.0; ICD10: C71, D33] | |||||
Breast cancer; Ovarian cancer [ICD9:174, 175, 183; ICD10: C50, C56] | |||||
BRCA-positive ovarian cancer [ICD10: C56] | |||||
Cerebrovascular ischaemia; Non-small cell lung cancer [ICD9:434.91; ICD10: I61-I63, C33-C34] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Melanoma [ICD9: 172; ICD10: C43] | |||||
Ovarian cancer [ICD9: 183; ICD10: C56] | |||||
Psoriatic arthritis [ICD9: 696; ICD10: L40.5, M07] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Type 2 diabetes [ICD9: 250; ICD10: E11] | |||||
BioChemical Class |
Transferases (EC:2)
|
||||
EC Number |
EC 2.4.2.30
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Olaparib | Drug Info | Approved | Breast cancer; Ovarian cancer | [542530], [550296] |
Rucaparib | Drug Info | Approved | BRCA-positive ovarian cancer | [889440] | |
ABT-888 | Drug Info | Phase 3 | Breast cancer | [524798], [542441] | |
BMN-673 | Drug Info | Phase 3 | Psoriatic arthritis | [524436], [543065] | |
BSI-201 | Drug Info | Phase 3 | Solid tumours | [531781], [543086] | |
INO-1001 | Drug Info | Phase 3 | Brain cancer | [527044], [530857] | |
Rucaparib | Drug Info | Phase 3 | Breast cancer; Ovarian cancer | [524484], [542704] | |
BGP-15 | Drug Info | Phase 2 | Type 2 diabetes | [526305], [531807] | |
E7016 | Drug Info | Phase 2 | Melanoma | [523915] | |
MK-4827 | Drug Info | Phase 2 | Ovarian cancer | [523258], [543030] | |
CEP-9722 | Drug Info | Phase 1/2 | Cerebrovascular ischaemia; Non-small cell lung cancer | [523387] | |
ABT-767 | Drug Info | Phase 1 | Solid tumours | [523443] | |
MP-124 | Drug Info | Phase 1 | Acute ischemic stroke | [531546] | |
ONO-2231 | Drug Info | Discontinued in Phase 1 | Cerebrovascular ischaemia | [548174] | |
Modulator | ABT-767 | Drug Info | [1572591] | ||
ABT-888 | Drug Info | [1572591] | |||
BGP-15 | Drug Info | [526305], [531807] | |||
BMN-673 | Drug Info | [1572591] | |||
BSI-201 | Drug Info | [531781] | |||
CEP-9722 | Drug Info | [1572591] | |||
E7016 | Drug Info | [1572591] | |||
INO-1001 | Drug Info | [527044], [530857] | |||
MK-4827 | Drug Info | [1572591] | |||
MP-124 | Drug Info | ||||
Olaparib | Drug Info | [533123] | |||
ONO-2231 | Drug Info | ||||
Rucaparib | Drug Info | [889440] | |||
References | |||||
Ref 523258 | ClinicalTrials.gov (NCT01244009) A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002). U.S. National Institutes of Health. | ||||
Ref 523387 | ClinicalTrials.gov (NCT01311713) Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 523443 | ClinicalTrials.gov (NCT01339650) Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. U.S. National Institutes of Health. | ||||
Ref 523915 | ClinicalTrials.gov (NCT01605162) Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma. U.S. National Institutes of Health. | ||||
Ref 524436 | ClinicalTrials.gov (NCT01945775) A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study). U.S. National Institutes of Health. | ||||
Ref 524484 | ClinicalTrials.gov (NCT01968213) A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. U.S. National Institutes of Health. | ||||
Ref 524798 | ClinicalTrials.gov (NCT02163694) A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 526305 | BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol. 2002 Mar 15;63(6):1099-111. | ||||
Ref 527044 | INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock. 2004 May;21(5):426-32. | ||||
Ref 530857 | Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12. | ||||
Ref 531546 | MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res. 2011 Sep 2;1410:122-31. | ||||
Ref 531781 | Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. | ||||
Ref 531807 | BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37. | ||||
Ref 542441 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417). | ||||
Ref 542530 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7519). | ||||
Ref 542704 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7736). | ||||
Ref 543030 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8275). | ||||
Ref 543065 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8313). | ||||
Ref 543086 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8360). | ||||
Ref 548174 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022742) | ||||
Ref 526305 | BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol. 2002 Mar 15;63(6):1099-111. | ||||
Ref 527044 | INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock. 2004 May;21(5):426-32. | ||||
Ref 530857 | Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12. | ||||
Ref 531781 | Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. | ||||
Ref 531807 | BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.